基于与1α,25-二羟基维生素D 3(1,25 D )结合的人类维生素D受体(hVDR)的晶体结构和超激动剂配体,我们先前设计了在侧链具有四氢呋喃环的新型超激动剂配体,从而优化了通过熵的好处实现脂肪族侧链构象。遵循类似的策略,四个具有芳香族呋喃侧链的新型维生素D类似物(3a,3b,4a,4b)现已开发。三烯体系的构建是通过对三氟甲磺酸酯(A环前体)进行高效的立体选择性分子内环化,然后将所得中间体与烯基硼酸酯(CD侧链,上部片段)进行铃木-宫浦偶联。呋喃侧链已通过金化学方法构建。这些类似物表现出显着的前分化作用和反式激活潜能。3 a的晶体结构与hVDR的配体结合结构域形成复合物,表明侧链呋喃环具有两个构象。
Total synthesis of 1α,25-dihydroxyvitamin D<sub>3</sub> (calcitriol) through a Si-assisted allylic substitution
作者:Borja López-Pérez、Miguel A. Maestro、Antonio Mouriño
DOI:10.1039/c7cc04690a
日期:——
Herein, we describe a versatile and efficient total synthesis of 1α,25-dihydroxyvitaminD3 (calcitriol). The synthetic strategy relies on an unprecedented Si-assisted SN2’-syn displacement of carbamates by cuprates to set the challenging pivotal quaternary methyl group at the fused-ring junction of the CD-trans-hydrindane core. Other key transformations involve the catalytic asymmetric reduction of
在这里,我们描述了1α,25-二羟基维生素D 3(骨化三醇)的通用有效的全合成方法。合成策略依赖于前所未有的Si辅助的氨基甲酸酯通过氨基甲酸酯置换S N 2'-氨基甲酸酯,以将具有挑战性的关键性季铵甲基基团设置在CD-反式-茚满核的稠环连接处。其他关键转化包括用CuH催化α,β,γ,δ-不饱和酯的催化不对称还原,以在C20处生成天然甾体构型,以及进行Pauson-Khand环化反应以形成CD环骨架。这种策略使得能够合成用于结构功能研究和药物开发的新型类似物。
An Expeditious Route to 1α,25-Dihydroxyvitamin D<sub>3</sub>and Its Analogues by an Aqueous Tandem Palladium-Catalyzed A-Ring Closure and Suzuki Coupling to the C/D Unit
mild, general, and highly stereoselectivePd0‐catalyzed cascade to the triene system of the hormone 1α,25‐dihydroxyvitamin D3 and six representative analogues is reported. The intramolecular cyclization of an enol–triflate (lower fragment) followed in situ by Suzuki–Miyaura coupling with an alkenyl boronic ester (upper fragment, also efficiently prepared by Pd0‐catalyzed coupling) in equimolar amounts
Total synthesis of 1α,25-dihydroxyvitamin D<sub>3</sub> analogs modified at the side chain and D-ring
作者:Borja López-Pérez、Miguel A. Maestro、Antonio Mouriño
DOI:10.1039/c8ob01002a
日期:——
we describe a synthetic strategy to access 1α,25-dihydroxyvitaminD3 (calcitriol) analogs with natural or unnatural configuration at C20 and unsaturation at the D-ring. The synthetic approach is exemplified by the synthesis of two potent analogs, namely 1α,25-dihydroxy-16-en-23-yne-vitamin D3 and 1α,25-dihydroxy-20-epi-24a-homo-26,27-dimethyl-vitamin D3. A key feature of the synthetic strategy is